Skip to main content
Journal cover image

The challenges of an HIV vaccine enterprise.

Publication ,  Journal Article
Zinkernagel, RM
Published in: Science
February 27, 2004

Duke Scholars

Published In

Science

DOI

EISSN

1095-9203

Publication Date

February 27, 2004

Volume

303

Issue

5662

Start / End Page

1294 / 1297

Location

United States

Related Subject Headings

  • Tuberculosis
  • Public Health
  • Immunity, Cellular
  • Humans
  • HIV Infections
  • Global Health
  • General Science & Technology
  • BCG Vaccine
  • AIDS Vaccines
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zinkernagel, R. M. (2004). The challenges of an HIV vaccine enterprise. Science, 303(5662), 1294–1297. https://doi.org/10.1126/science.303.5662.1294
Zinkernagel, Rolf M. “The challenges of an HIV vaccine enterprise.Science 303, no. 5662 (February 27, 2004): 1294–97. https://doi.org/10.1126/science.303.5662.1294.
Zinkernagel RM. The challenges of an HIV vaccine enterprise. Science. 2004 Feb 27;303(5662):1294–7.
Zinkernagel, Rolf M. “The challenges of an HIV vaccine enterprise.Science, vol. 303, no. 5662, Feb. 2004, pp. 1294–97. Pubmed, doi:10.1126/science.303.5662.1294.
Zinkernagel RM. The challenges of an HIV vaccine enterprise. Science. 2004 Feb 27;303(5662):1294–1297.
Journal cover image

Published In

Science

DOI

EISSN

1095-9203

Publication Date

February 27, 2004

Volume

303

Issue

5662

Start / End Page

1294 / 1297

Location

United States

Related Subject Headings

  • Tuberculosis
  • Public Health
  • Immunity, Cellular
  • Humans
  • HIV Infections
  • Global Health
  • General Science & Technology
  • BCG Vaccine
  • AIDS Vaccines